Foghorn Therapeutics(US:FHTX)2022-03-12 15:56Overview - The dysregulation of the Chromatin Regulatory System is implicated in approximately 50% of all cancers, representing a significant market opportunity[3] - Foghorn Therapeutics is well-positioned to discover and develop first-in-class precision medicines targeting cancer and other diseases[4] - Foghorn Therapeutics had $479.5 million in pro forma cash and equivalents as of September 30, 2021[5] Pipeline and Programs - FHD-286 (BRG1/BRM) is an enzyme inhibitor targeting AML and Uveal melanoma, with initial clinical data expected in H1 2022[8, 23] - FHD-609 (BRD9) is a protein degrader targeting Synovial Sarcoma, with initial clinical data expected as early as H1 2022[8, 23] - Selective BRM modulators, including enzyme inhibitors and protein degraders, are being developed for BRG1 mutated cancers, impacting over 100,000 patients per year[52] - Selective ARID1B protein degrader is in pre-clinical development for ARID1A mutated cancers, potentially impacting over 175,000 patients per year[60] Strategic Collaborations - Strategic collaboration with Loxo Oncology at Lilly includes $380 million upfront ($300 million cash and $80 million in Foghorn common stock at $20 per share), 50/50 U S economics on two programs, tiered ex-U S royalties, and $1.3 billion in potential milestones[10] - Merck collaboration to drug single specified transcription factor target includes $425 million in up-front, research, development and sales-based milestones and up to low double-digit royalties on product sales[68]